QCT Collaborates with Samsung and Intel to Lead Transition to PCIe Gen5 with Next-Generation Servers and SSDs
26.7.2022 06:51:00 EEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced the world’s first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe™ servers powered by 4th Gen Intel® Xeon® Scalable processors. 4th Gen Intel Xeon Scalable processors will deliver substantial compute performance across traditional data center usages with unique purpose-built workload optimizations for today’s edge to cloud models. These technology updates in QCT’s growing line of QuantaGrid servers add additional performance for Samsung’s high-bandwidth flash storage due to the 4th Gen Intel Xeon Scalable processors support of leading industry standard technologies such as DDR5, Intel® Optane™ persistent memory, and PCIe Gen5. Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005386/en/
SVP & GM of QCT, Mike Yang (left) and EVP of Samsung Electronics, Yongcheol Bae (right) announce collaboration to pioneer PCIe Gen5 SSD systems (Photo: Business Wire)
To accommodate the rapidly increasing performance requirements of data centers, PCIe Gen5 doubles IOPS per watt and throughput compared to the previous generation. Samsung’s PM1743 SSD for enterprise servers integrates the PCIe Gen5 interface with Samsung’s advanced sixth-generation V-NAND to deliver 30% enhanced power efficiency than the previous generation, resulting in lower server operating costs and increasing scalability for virtualized environments like HCI and software-defined storage.
With the evolution of data centers to the rapid growth of data and proliferation of applications that demand high performance, QCT’s upcoming QuantaGrid series offer flexibility for scaling out with Samsung’s new storage innovation. The QuantaGrid D54X-1U and D54Q-2U are designed for dual 4th Gen Intel Xeon Scalable processors with 32 DDR5 DIMM slots and support for Intel Optane persistent memory, which provides affordable memory capacity expansion and support for data persistence. The two servers mainly differ in storage capacity and number of expansion slots that will be further revealed with the release of 4th Gen Intel Xeon Scalable processors.
“QCT worked closely with Samsung to test and be among the first to validate Samsung’s PM1743 PCIe Gen5 SSDs on our Intel powered systems,” said Mike Yang, President of QCT. “Together with Samsung, and Intel, our technology leadership will continue to drive new applications as we accelerate the growth of the server market and deliver unparalleled performance advantages for IOPS-intensive applications.”
"Samsung has been working closely with QCT and Intel to show PCIe Gen5 PM1743 SSDs provide optimized performance for all-flash NVMe workloads in their QuantaGrid 1U and 2U systems," said Yongcheol Bae, Executive Vice President of the Memory Application Engineering Team at Samsung Electronics. “Collectively, with the introduction of our PCIe Gen5 SSD, Intel’s 4th Gen Xeon Scalable processors, and QCT’s QuantaGrid server line we will further solidify our technological leadership in the enterprise server market.”
“Our goal is to deliver industry leadership to accelerate data center performance and user experiences with our upcoming 4th Gen Intel Xeon Scalable processors,” said Zane Ball, Intel Corporate Vice President and General Manager of Data Platforms Engineering and Architecture. “The collaboration with QCT and Samsung signifies Intel’s commitment to providing our customers with a multitude of ways to enhance their applications with high-speed NVMe SSDs that enable deployments from edge to cloud.”
Follow QCT on Facebook and Twitter to receive their latest news and announcements.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT
QCT is a global datacenter solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. www.QCT.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005386/en/
Contact information
Janet Chang
Janet.chang@quantatw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom